Movella Holdings Inc., a world leader in the digitization of movement, is providing critical technology to researchers tracking the onset of movement-altering diseases. Movella’s Xsens motion capture technology is used in medical research to develop new examination methodologies and treatments
Henderson, Nevada, April 18, 2023 – Researchers at Imperial College and University College London, led by Professor Aldo Faisal, have spent seven years conducting in-depth studies on the progression of Friedreich’s ataxia (FA) and Duchenne muscular dystrophy (DMD). Using Xsens motion capture allows for quick and accurate assessments of a patient’s movement, detecting subtle movements that human analysis alone cannot. Studies on FA and DMD, published in Nature Medicine, demonstrate efficacy of motion capture data to predict the worsening of degenerative nerve conditions. Evaluating the efficacy of a movement-enhancing drug often involves patients who find it difficult to walk for long periods of time. By analyzing the digitized motion data generated by the Xsens suit, this burden is minimized to a matter of steps, enabling medical professionals to predict the progression of these diseases in half the time it would normally take. “We believe that the application of Movella’s technology has the potential to change the economics of drug discovery,” said Dr. Aldo Faisal, Professor of Artificial Intelligence and Neuroscience at Imperial College London. “With motion capture, we have been able to create a whole new field of study: atomics. It will attract the pharmaceutical industry to invest in rare diseases, but the main beneficiary of our research is going to be patients. The technology will be able to hit all the new treatments faster.” “The impact that motion capture will have on the development of new drugs and diagnostics for a number of diseases will be enormous,” said CJ Hoogsteen, vice president of sales and marketing for Movella. “By using Movella’s Xsens solutions, medical professionals can reduce the time and cost required to develop new drugs in clinical trials and make it more cost-effective to test new drugs for rare genetic disorders.” The team is already seeking approval for the use of Movella’s solutions in clinical drug trials, which will begin within two years. Additional research on Parkinson’s, Alzheimer’s, and MS is currently underway. About Movella Holdings Inc. Movella is a leading provider of sensors, software, and analytics that enable the digitization of movement. Movella serves the entertainment, health and sports, and automation and mobility markets. Our innovations enable clients to capitalize on the value of movement by transforming data into meaningful and actionable information. In collaboration with leading global brands like Electronic Arts, EPIC Games, 20th Century Studios, Netflix, Toyota, Siemens, and more than 500 sports organizations, Movella is creating extraordinary results that move humanity forward. For more information, visit www.movella .com.Issuer: Movella Holdings Inc
Contact Contact name: Remco Sikkema Contact description: Contact telephone number: 31-88-9736700
